2014
Pernicová, Zuzana; Slabáková, Eva; Fedr, Radek; Šimečková, Šárka; Jaroš, Josef; Suchánková, Tereza; Bouchal, Jan; Kharaishvili, Gvantsa; Král, Milan; Kozubík, Alois; Souček, Karel
The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Journal Article
In: Molecular cancer, vol. 13, pp. 113, 2014, ISSN: 1476-4598, (Place: England).
Abstract | Links | BibTeX | Tags: *Cell Transdifferentiation/drug effects, Androgen/metabolism, Androgens/pharmacology, CDC2 Protein Kinase, Cell Count, Cell Cycle Checkpoints/drug effects, Cell Line, Cyclic AMP/metabolism, Cyclin-Dependent Kinase 2/metabolism, Cyclin-Dependent Kinases/metabolism, Epithelial Cells/drug effects/enzymology/pathology, Humans, Immunohistochemistry, Male, Neuroendocrine Cells/drug effects/*pathology, Prostatic Neoplasms/*pathology, Protein Kinase Inhibitors/pharmacology, Receptors, Signal Transduction/drug effects, Tumor
@article{pernicova_role_2014,
title = {The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.},
author = {Zuzana Pernicová and Eva Slabáková and Radek Fedr and Šárka Šimečková and Josef Jaroš and Tereza Suchánková and Jan Bouchal and Gvantsa Kharaishvili and Milan Král and Alois Kozubík and Karel Souček},
doi = {10.1186/1476-4598-13-113},
issn = {1476-4598},
year = {2014},
date = {2014-05-01},
journal = {Molecular cancer},
volume = {13},
pages = {113},
abstract = {BACKGROUND: Tumor heterogeneity and the plasticity of cancer cells present challenges for effective clinical diagnosis and therapy. Such challenges are epitomized by neuroendocrine transdifferentiation (NED) and the emergence of neuroendocrine-like cancer cells in prostate tumors. This phenomenon frequently arises from androgen-depleted prostate adenocarcinoma and is associated with the development of castration-resistant prostate cancer and poor prognosis. RESULTS: In this study, we showed that NED was evoked in both androgen receptor (AR)-positive and AR-negative prostate epithelial cell lines by growing the cells to a high density. Androgen depletion and high-density cultivation were both associated with cell cycle arrest and deregulated expression of several cell cycle regulators, such as p27Kip1, members of the cyclin D protein family, and Cdk2. Dual inhibition of Cdk1 and Cdk2 using pharmacological inhibitor or RNAi led to modulation of the cell cycle and promotion of NED. We further demonstrated that the cyclic adenosine 3', 5'-monophosphate (cAMP)-mediated pathway is activated in the high-density conditions. Importantly, inhibition of cAMP signaling using a specific inhibitor of adenylate cyclase, MDL-12330A, abolished the promotion of NED by high cell density. CONCLUSIONS: Taken together, our results imply a new relationship between cell cycle attenuation and promotion of NED and suggest high cell density as a trigger for cAMP signaling that can mediate reversible NED in prostate cancer cells.},
note = {Place: England},
keywords = {*Cell Transdifferentiation/drug effects, Androgen/metabolism, Androgens/pharmacology, CDC2 Protein Kinase, Cell Count, Cell Cycle Checkpoints/drug effects, Cell Line, Cyclic AMP/metabolism, Cyclin-Dependent Kinase 2/metabolism, Cyclin-Dependent Kinases/metabolism, Epithelial Cells/drug effects/enzymology/pathology, Humans, Immunohistochemistry, Male, Neuroendocrine Cells/drug effects/*pathology, Prostatic Neoplasms/*pathology, Protein Kinase Inhibitors/pharmacology, Receptors, Signal Transduction/drug effects, Tumor},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Tumor heterogeneity and the plasticity of cancer cells present challenges for effective clinical diagnosis and therapy. Such challenges are epitomized by neuroendocrine transdifferentiation (NED) and the emergence of neuroendocrine-like cancer cells in prostate tumors. This phenomenon frequently arises from androgen-depleted prostate adenocarcinoma and is associated with the development of castration-resistant prostate cancer and poor prognosis. RESULTS: In this study, we showed that NED was evoked in both androgen receptor (AR)-positive and AR-negative prostate epithelial cell lines by growing the cells to a high density. Androgen depletion and high-density cultivation were both associated with cell cycle arrest and deregulated expression of several cell cycle regulators, such as p27Kip1, members of the cyclin D protein family, and Cdk2. Dual inhibition of Cdk1 and Cdk2 using pharmacological inhibitor or RNAi led to modulation of the cell cycle and promotion of NED. We further demonstrated that the cyclic adenosine 3', 5'-monophosphate (cAMP)-mediated pathway is activated in the high-density conditions. Importantly, inhibition of cAMP signaling using a specific inhibitor of adenylate cyclase, MDL-12330A, abolished the promotion of NED by high cell density. CONCLUSIONS: Taken together, our results imply a new relationship between cell cycle attenuation and promotion of NED and suggest high cell density as a trigger for cAMP signaling that can mediate reversible NED in prostate cancer cells.
2011
Pernicová, Zuzana; Slabáková, Eva; Kharaishvili, Gvantsa; Bouchal, Jan; Král, Milan; Kunická, Zuzana; Machala, Miroslav; Kozubík, Alois; Souček, Karel
Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Journal Article
In: Neoplasia (New York, N.Y.), vol. 13, no. 6, pp. 526–536, 2011, ISSN: 1476-5586 1522-8002, (Place: United States).
Abstract | Links | BibTeX | Tags: Androgen Antagonists/*pharmacology, Androgen/metabolism, beta-Galactosidase/metabolism, Blotting, Cathepsin B/metabolism, Cell Line, Cellular Senescence/*drug effects, Confocal, Down-Regulation/*drug effects, Flow Cytometry, Humans, Insulin-Like Growth Factor Binding Protein 3/metabolism, Male, Microscopy, Prostatic Neoplasms/genetics/metabolism/pathology, PTEN Phosphohydrolase/metabolism, Receptors, RNA Interference, S-Phase Kinase-Associated Proteins/genetics/*metabolism, Signal Transduction/drug effects, Tumor, Vimentin/metabolism, Western
@article{pernicova_androgen_2011,
title = {Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2.},
author = {Zuzana Pernicová and Eva Slabáková and Gvantsa Kharaishvili and Jan Bouchal and Milan Král and Zuzana Kunická and Miroslav Machala and Alois Kozubík and Karel Souček},
doi = {10.1593/neo.11182},
issn = {1476-5586 1522-8002},
year = {2011},
date = {2011-06-01},
journal = {Neoplasia (New York, N.Y.)},
volume = {13},
number = {6},
pages = {526–536},
abstract = {Although the induction of senescence in cancer cells is a potent mechanism of tumor suppression, senescent cells remain metabolically active and may secrete a broad spectrum of factors that promote tumorigenicity in neighboring malignant cells. Here we show that androgen deprivation therapy (ADT), a widely used treatment for advanced prostate cancer, induces a senescence-associated secretory phenotype in prostate cancer epithelial cells, indicated by increases in senescence-associated β-galactosidase activity, heterochromatin protein 1β foci, and expression of cathepsin B and insulin-like growth factor binding protein 3. Interestingly, ADT also induced high levels of vimentin expression in prostate cancer cell lines in vitro and in human prostate tumors in vivo. The induction of the senescence-associated secretory phenotype by androgen depletion was mediated, at least in part, by down-regulation of S-phase kinase-associated protein 2, whereas the neuroendocrine differentiation of prostate cancer cells was under separate control. These data demonstrate a previously unrecognized link between inhibition of androgen receptor signaling, down-regulation of S-phase kinase-associated protein 2, and the appearance of secretory, tumor-promoting senescent cells in prostate tumors. We propose that ADT may contribute to the development of androgen-independent prostate cancer through modulation of the tissue microenvironment by senescent cells.},
note = {Place: United States},
keywords = {Androgen Antagonists/*pharmacology, Androgen/metabolism, beta-Galactosidase/metabolism, Blotting, Cathepsin B/metabolism, Cell Line, Cellular Senescence/*drug effects, Confocal, Down-Regulation/*drug effects, Flow Cytometry, Humans, Insulin-Like Growth Factor Binding Protein 3/metabolism, Male, Microscopy, Prostatic Neoplasms/genetics/metabolism/pathology, PTEN Phosphohydrolase/metabolism, Receptors, RNA Interference, S-Phase Kinase-Associated Proteins/genetics/*metabolism, Signal Transduction/drug effects, Tumor, Vimentin/metabolism, Western},
pubstate = {published},
tppubtype = {article}
}
Although the induction of senescence in cancer cells is a potent mechanism of tumor suppression, senescent cells remain metabolically active and may secrete a broad spectrum of factors that promote tumorigenicity in neighboring malignant cells. Here we show that androgen deprivation therapy (ADT), a widely used treatment for advanced prostate cancer, induces a senescence-associated secretory phenotype in prostate cancer epithelial cells, indicated by increases in senescence-associated β-galactosidase activity, heterochromatin protein 1β foci, and expression of cathepsin B and insulin-like growth factor binding protein 3. Interestingly, ADT also induced high levels of vimentin expression in prostate cancer cell lines in vitro and in human prostate tumors in vivo. The induction of the senescence-associated secretory phenotype by androgen depletion was mediated, at least in part, by down-regulation of S-phase kinase-associated protein 2, whereas the neuroendocrine differentiation of prostate cancer cells was under separate control. These data demonstrate a previously unrecognized link between inhibition of androgen receptor signaling, down-regulation of S-phase kinase-associated protein 2, and the appearance of secretory, tumor-promoting senescent cells in prostate tumors. We propose that ADT may contribute to the development of androgen-independent prostate cancer through modulation of the tissue microenvironment by senescent cells.